Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | BRS3 | P32247 | 7/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | SPR | P35270 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27034279 | 0.88 | TRPV4 (0.44) | TRPV4KDM4EALDH1A1BRS3NR1I2 | |
| SCHEMBL26064736 | 0.87 | TRPV4 (0.42) | TRPV4KDM4EALDH1A1TSHRKMT2A | |
| SCHEMBL27070045 | 0.83 | KMT2A (0.47) | TRPV4KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL25365499 | 0.83 | TRPV4 (0.40) | TRPV4KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL25366630 | 0.81 | TSHR (0.36) | TRPV4ALDH1A1TSHRKMT2AMEN1 | |
| SCHEMBL27034555 | 0.80 | TRPV4 (0.38) | TRPV4ALDH1A1TSHRBRS3NR1I2 | |
| SCHEMBL26065736 | 0.80 | ALDH1A1 (0.48) | TRPV4KDM4EALDH1A1TSHRKMT2A | |
| SCHEMBL25363280 | 0.80 | SMN1; SMN2 (0.39) | TRPV4KDM4EALDH1A1TSHRKMT2A | |
| SCHEMBL25363921 | 0.80 | TRPV4 (0.42) | TRPV4KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL26064728 | 0.80 | NAMPT (0.43) | TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250152574-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. | 2025-05-15 | — | — | US | disclosed |
| EP-4479384-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | Biogen MA Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| WO-2023154499-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023154499-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. (US) | 2023-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250152574-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | EBPL, EBP, CREBBP | TRPV4 4560/4885KDM4E 2417/4885ALDH1A1 3089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.